Life Sciences Research Reagents and Supplies Bi-Weekly Industry Events & M&A Update — September 14–28, 2026

Read the report

SlidesScroll

1 of 7

←→Full screen

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › LIFE SCIENCES RESEARCH REAGENTS AND SUPPLIES

Execution News Lifts the Whole Set While Deal Flow Waits

What moved across Life Sciences Research Reagents and Supplies over the two-week period of September 14–28, 2026.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Life Sciences Research Reagents and Supplies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

Sources & methodology

1

← Previous

1 / 7 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › LIFE SCIENCES RESEARCH REAGENTS AND SUPPLIES

Next →

What each page shows

The analyst’s walkthrough of the deck, page by page.

1. 01
   BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

   HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › LIFE SCIENCES RESEARCH REAGENTS AND SUPPLIES

   Cover slide introducing the bi-weekly industry events and M&A update for Life Sciences Research Reagents and Supplies, September 14–28, 2026.

   We open with the two-week scorecard for Life Sciences Research Reagents and Supplies, covering what changed, who moved, what transacted, and what it means. This update tracks the period from September 14 to 28, 2026, giving a clear read on where execution and deal activity stood so you can act on the current picture.

   Everything on this page

   BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › LIFE SCIENCES RESEARCH REAGENTS AND SUPPLIES Execution News Lifts the Whole Set While Deal Flow Waits What moved across Life Sciences Research Reagents and Supplies over the two-week period of September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Life Sciences Research Reagents and Supplies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

2. 02
   THE BI-WEEKLY BOTTOM LINE

   Company Execution, Not Transactions, Carried the Period

   Summarizes the two-week period across the 9 covered names, comparing their moves to the S&P 500.

   We start with the headline: all 9 covered names finished the period higher, with a sector median move of +22.5% against +0.8% for the S&P 500. That breadth tells us this was a company-level story, not a single outlier. We'll walk through the biggest movers and what drove them next, so you can see where the real signal sits.

   Everything on this page

   THE BI-WEEKLY BOTTOM LINE Company Execution, Not Transactions, Carried the Period The two-week period in one page · 9 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Life Sciences Research Reagents and Supplies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 Every Covered Name Finished the Two-Week Period Higher 9 of 9 covered names rose; the median move was +22.5%. The S&P 500 returned +0.8% over the same window. 2 The Two Largest Gainers Both Carried Their Own In-Window News Quanterix Corporation (QTRX) rose +40.8% and Alpha Teknova, Inc. (TKNO) rose +34.9%. Each had a product or leadership announcement inside the window. 3 No New Transaction Priced the Set This Period No material sector transactions were announced during the period. The trailing record of 20 precedent transactions still carries a median of 24.2x EV/EBITDA. 4 A Two-Week Rally Does Not Move the Standing Tiers NeuraCap's standing view reads this set on EV / Revenue, with a 9.1x sector median for CY2027E and a Premium tier median of 16.7x. The period's moves are consistent with that frame rather than a challenge to it. +40.8% Best mover — Quanterix Corporation (QTRX) worst: SEER +6.3% · 9 up / 0 down of 9 covered +22.5% Sector median two-week return vs S&P 500 +0.8%

3. 03
   PUBLIC MARKET MOVERS

   Product Capacity and Senior Hires Drove the Period's Biggest Moves

   Ranks the period's largest share-price moves and ties them to product and leadership news.

   Quanterix Corporation rose +40.8% and Alpha Teknova rose +34.9%, the two largest moves this period, each linked to a specific product or leadership announcement inside the window. The sector median move of +22.5% sits below our +33.7% materiality bar, which sharpens which stories actually matter. We only attribute a move to a driver where a filing or headline is recorded in the window, so what you see here is evidence, not speculation. That discipline is what makes these two names worth a closer look.

   Everything on this page

   PUBLIC MARKET MOVERS Product Capacity and Senior Hires Drove the Period's Biggest Moves Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median +22.5% · S&P 500 +0.8% · materiality bar ±33.7% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Life Sciences Research Reagents and Supplies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median +22.5% Quanterix Corporation (QTRX) +40.8% Shares moved following two company announcements in the window: the September 14 appointment of Dr. Yuri Fesko as Chief Medical Officer, and the inducement grants reported on September 16. The largest single day was Sep 15 at +8.8%. A NeuraCap read: Discount-tier names can move hard when the market sees hiring aimed at the clinical path. COMPANY-SPECIFIC Alpha Teknova, Inc. (TKNO) +34.9% The move appears to reflect the Fill-Tek dispensing system announced on September 16, which fills single-use bag orders across multiple sizes as a single lot with no added turnaround time. The largest single day was Sep 21 at +7.1%. Core-tier suppliers get paid for custom and bulk manufacturing capacity, not only for catalog SKUs. COMPANY-SPECIFIC

4. 04
   MAJOR NEWS & INDUSTRY CATALYSTS

   Companies Spent the Period Adding Capacity, Content and Leadership

   Details the period's highest-impact company events, including capacity, content and leadership additions.

   The period's news flow centered on companies adding capacity, content and leadership rather than closing deals. Each event on this page links back to its underlying filing or article, and our "why it matters" read is kept separate from the sourced fact. This is where the share-price moves on the prior page trace back to their origin, so you can judge the evidence yourself.

   Everything on this page

   MAJOR NEWS & INDUSTRY CATALYSTS Companies Spent the Period Adding Capacity, Content and Leadership The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Life Sciences Research Reagents and Supplies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 23 · NEWS · Business Wire Thermo Fisher launches the Gibco CHO-K1 catalog panel of media and feed for biologics work A cGMP-ready basal and feed portfolio aimed at bioproduction adds catalog SKUs where reorders follow the process rather than the instrument. That is the spec-in position the diversified platforms keep building toward. Regulated-grade media is where the largest suppliers are choosing to compete for repeat orders. Sep 21 · NEWS · GlobeNewsWire Seer announces a transition in its Chief Financial Officer role At a platform-stage proteomics name, the finance seat sits closest to the placement-to-pull-through story the market is underwriting. A change there is worth watching for how the recurring mix is framed. Leadership continuity carries weight when the revenue model is still converting instruments into kits. Sep 16 · NEWS · Business Wire Twist Bioscience joins Lilly TuneLab to advance antibody drug discovery A Premium-tier name putting its synthetic DNA capability inside a partner's AI discovery platform is a route to being spec'd into someone else's workflow. Biopharma-weighted demand is the steadier end of the mix. Partnerships with biopharma platforms can build attach rate without new instrument placements. Sep 16 · NEWS · GlobeNewsWire Teknova expands custom manufacturing with the Fill-Tek single-use bag filling system Filling multiple bag sizes and quantities as a single lot with no added turnaround speaks directly to lot-to-lot consistency and lead time in bioproduction supply. Those are the terms on which custom accounts stay. Custom and bulk mix is where Core-tier suppliers separate themselves from commodity consumables. Sep 16 · NEWS · Business Wire Quanterix reports inducement grants made to a recently appointed senior executive The grants sit alongside a run of senior appointments in the same window. The signal is a company building out commercial and clinical leadership rather than trimming it. Where a company hires at the top says where it expects its next revenue to come from. Sep 14 · NEWS · Business Wire Quanterix appoints Dr. Yuri Fesko as Chief Medical Officer Putting a physician executive in a new Chief Medical Officer seat points at the research-use-only to regulated-grade path, which is where durability in biomarker franchises is decided. Clinical leadership hires mark intent to move product toward regulated grade.

5. 05
   M&A & STRATEGIC ACTIVITY

   The Reference Set Stands on the Trailing Record This Period

   Shows the trailing precedent transaction record of 20 deals with a median 24.2x EV/LTM EBITDA multiple, noting no new deals this period.

   No new transactions were announced in this window, so the reference point for anyone thinking about a deal remains the trailing record: 20 precedent transactions at a median 24.2x EV/LTM EBITDA. We treat that record as the standing benchmark until a new deal adds to it. For acquirers and targets alike, this means the two-week share-price rally has not yet been tested against a live transaction.

   Everything on this page

   M&A & STRATEGIC ACTIVITY The Reference Set Stands on the Trailing Record This Period September 14–28, 2026 · precedent transactions: 20 recorded deals · median 24.2x EV/LTM EBITDA Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Life Sciences Research Reagents and Supplies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. The pricing evidence remains the trailing record of 20 precedent transactions, which carries a median of 24.2x EV/EBITDA. A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 20 Recorded precedent transactions the reference set buyers and sellers price against 24.2x Precedent median EV/LTM EBITDA LTM at announcement, where disclosed

6. 06
   WHAT IT MEANS

   What a Broad, News-Led Rally Means for People Running These Businesses

   Translates the period's findings into distinct takeaways for owners, acquirers and advisors.

   For owners and operators, this period shows that operating news, not market noise, set the prices. For acquirers, the message is that share prices moved but the transaction evidence did not, leaving the 24.2x EV/EBITDA precedent median as the still-relevant reference. For advisors, the playbook is to lead with execution evidence, since the period's stories were about capacity, partnerships and senior hires. Together these reads point to the same conclusion: this was an execution-led period, and the deal record has not yet caught up.

   Everything on this page

   WHAT IT MEANS What a Broad, News-Led Rally Means for People Running These Businesses The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Life Sciences Research Reagents and Supplies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 9.1x 9 companies in the study 3 valuation tiers Standing thesis: Life Sciences Research Reagents and Supplies Trades as Four Businesses, and the Faster Growers Hold the Top FOR OWNERS & OPERATORS Operating News Set the Prices This Period Companies in the space traded higher across the board, and the two largest gainers each carried their own product or leadership announcement. FOR ACQUIRERS Share Prices Moved; The Transaction Evidence Did Not No new transactions were signed in the window, so the trailing record of 20 precedent transactions and its 24.2x EV/EBITDA median is still the reference point. FOR ADVISORS Lead with Execution Evidence This Period The theme was company execution: a media and feed launch, a biopharma discovery partnership, added custom fill capacity, and senior hires.

7. 07
   SOURCES & METHODOLOGY

   Sources, Methodology and Important Notice

   Explains the sources and methodology behind every figure and claim in this update.

   Every figure in this update links back to the record it came from, whether a filing, a press release or an established outlet. We hold to a fixed source order and never draw on video or social platforms, so what you see here is traceable and repeatable. This page is your reference if you want to verify anything on the prior six.

   Everything on this page

   SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Life Sciences Research Reagents and Supplies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. No covered name fell below the floor in this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T212310Z_571_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: businesswire.com · globenewswire.com

More coverage in Health Care

• Sector Report · Sep 28, 2026Life Sciences Research Reagents and Supplies Sector Outlook — September 2026
• Sector Report · Sep 28, 2026Medical Imaging Equipment Sector Outlook — September 2026
• Bi-Weekly Update · Sep 28, 2026Neurology and CNS Therapeutics Bi-Weekly Industry Events & M&A Update — September 14–28, 2026
• Sector Report · Sep 28, 2026Neurology and CNS Therapeutics Sector Outlook — September 2026